Solid Quarter For Smith & Nephew Plc

Strong growth in emerging markets helps offset weaker Europe for Smith & Nephew plc (LON:SN).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Smith & Nephew (LSE: SN) reported 4% growth in revenue in the second quarter as sales picked up after a slower first quarter. Unfortunately, profits didn’t follow as pricing pressure, restructuring and acquisition costs, and investment in sales and R&D resulted in operating profits sliding 10%.

Adjusted earnings — which management helpfully adjusts for supposed one-time costs — were up very slightly to 18p.

As has been the case recently, Smith & Nephew’s results were a tale of two businesses. The company’s legacy hip and knee replacement operations continue to struggle as health concerns around metal-on-metal hip joints and competitors beating the company to market with newer and shinier knee models take their toll. The economic pains in Europe also don’t help.

Better news came from the Advanced Wound Management division — focused on treating chronic wounds like those suffered by diabetes patients — which reported sales up 30% (still up 10% even if we back out gains from an acquisition made in the last year).

Emerging markets also provided relief as sales to these countries were up 16% — the third consecutive quarter of double-digit growth.

Management has outlined wound management and emerging markets as the company’s growth drivers going forward, so this quarter’s successes are encouraging. However, these two categories only make up 31% and 13% of the company’s revenue, respectively, which means investors would like to see some recovery in the joint-replacement department.

In the meantime, the company’s new plan to return more cash to shareholders via a higher dividend payout — the interim dividend was raised 5% — and share buybacks — $75 million of the planned $300 million has been spent so far — has apparently pleased the market.

Smith & Nephew currently trades near its all-time highs although a price-to-earnings ratio around 15 doesn’t look too stretched.

The medical device industry is attractive because high barriers to entry mean companies can demand premium pricing and the world demographics — rapid aging and growing incomes — indicate a growing target market.

However, the real growth for Smith & Nephew will come from delivering on its efforts to tap into the lower-income, but faster growing markets like Brazil, India, and Turkey. The question is, can it do so profitably?

If you’re undecided about Smith & Nephew’s chances, but are looking to invest in growth opportunities you should read this free report on The Motley Fool’s favourite growth share for 2013.

You can get the free report just by clicking here.

> Nate does not own shares of Smith & Nephew. The Motley Fool owns shares of Smith & Nephew.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

More on Company Comment

Hand of person putting wood cube block with word VALUE on wooden table
Company Comment

Value has been building behind the Diageo share price

Despite the business growing, the Diageo share price first reached its current level just over 19 months ago and hasn't…

Read more »

Older couple walking in park
Investing Articles

5 stocks to buy for high and rising dividend income

I can see a host of shares to buy on the FTSE 100 offering me exceptional levels of income. Here…

Read more »

Young mixed-race woman looking out of the window with a look of consternation on her face
Investing Articles

I don’t care if FTSE 100 shares fall further, I’m buying them today

I'm happy to go shopping for FTSE 100 shares today, even though I accept that they could have further to…

Read more »

Happy young female stock-picker in a cafe
Investing Articles

Rolls-Royce shares are down 18% in a month and I’m finally going to buy them

Investors who bought Rolls-Royce shares have been repeatedly disappointed, but I'm willing to take a chance on them before they…

Read more »

Storytelling image of a multiethnic senior couple in love - Elderly married couple dating outdoors, love emotions and feelings
Investing Articles

How I’d invest £10k in a Stocks and Shares ISA today

Now looks like a good time to buy cheap FTSE 100 shares inside a Stocks and Shares ISA. These are…

Read more »

Black father holding daughter in a field of cows
Investing Articles

Today’s financial crisis is the perfect moment to buy cheap shares

I'm building a portfolio of FTSE 100 stocks by purchasing cheap shares whenever I see an opportunity. There's a good…

Read more »

Long-term vs short-term investing concept on a staircase
Investing Articles

I’d buy Tesco shares in October to bag their 5.4% yield 

Tesco shares have fallen lately but I think this makes them attractively valued for a dividend stock I would aim…

Read more »

Young mixed-race woman looking out of the window with a look of consternation on her face
Investing Articles

I would do anything to hold Diageo in my portfolio (but I won’t do that)

Diageo is one of my favourite stocks on the entire FTSE 100 and I'd love to hold it, but one…

Read more »